Heat-stable ritonavir tablet may be available next year
A new developmental 100 mg tablet version of the protease inhibitor ritonavir (Norvir) which will not require refrigeration is now in late stage development. It appears to be equivalent to the current soft-gel capsule formulation in terms of side-effects and potency.
Ritonavir is predominantly used as a booster for other protease inhibitors. Ritonavir’s manufacturer Abbott will seek approval for the drug later this year.